Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
185 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02823574 | Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(CheckMate 714) | completed | Phase 2 | 425 | Bristol-Myers SquibbINDUSTRY | 21 | May 3, 2023 | clinicaltrials |
| NCT04766229 | The Menopause After Cancer Study(MACS) | completed | Phase 2 | 205 | University College DublinOTHER | 1 |
| Jan 6, 2023 |
| clinicaltrials |
| NCT02409368 | An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC(Checkmate 171) | completed | Phase 2 | 812 | Bristol-Myers SquibbINDUSTRY | 13 | Nov 14, 2022 | clinicaltrials |
| NCT02651987 | Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg(CLARINET FORTE) | completed | Phase 2 | 99 | IpsenINDUSTRY | 10 | Oct 3, 2022 | clinicaltrials |
| NCT03410693 | Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma(FORT-1) | completed | Phase 2 / Phase 3 | 175 | BayerINDUSTRY | 29 | Sep 28, 2022 | clinicaltrials |
| NCT02610777 | An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 120 | Millennium Pharmaceuticals, Inc.INDUSTRY | 12 | Sep 19, 2022 | clinicaltrials |
| NCT00828854 | Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing | completed | Phase 2 | 27 | Syndax PharmaceuticalsINDUSTRY | 2 | Jun 30, 2022 | clinicaltrials |
| NCT03322566 | A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06) | completed | Phase 2 | 233 | Incyte CorporationINDUSTRY | 14 | Jan 24, 2022 | clinicaltrials |
| NCT01566747 | Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5 | completed | Phase 2 | 43 | Cancer Trials IrelandNETWORK | 2 | Dec 23, 2021 | clinicaltrials |
| NCT05156424 | A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer | unknown | Phase 1 / Phase 2 | 24 | Kira MurphyOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT01303172 | A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer | completed | Phase 2 | 110 | Immodulon Therapeutics LtdINDUSTRY | 5 | Nov 10, 2021 | clinicaltrials |
| NCT02458638 | A Study of Atezolizumab in Advanced Solid Tumors | completed | Phase 2 | 474 | Hoffmann-La RocheINDUSTRY | 18 | Jun 4, 2021 | clinicaltrials |
| NCT01783444 | A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.(BOLERO-6) | completed | Phase 2 | 309 | Novartis PharmaceuticalsINDUSTRY | 18 | Feb 26, 2021 | clinicaltrials |
| NCT01298570 | Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer | completed | Phase 2 | 181 | UNC Lineberger Comprehensive Cancer CenterOTHER | 2 | Jan 6, 2021 | clinicaltrials |
| NCT00760929 | A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC). | terminated | Phase 2 | 171 | Hoffmann-La RocheINDUSTRY | 11 | Jan 5, 2021 | clinicaltrials |
| NCT00942162 | A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma(PREDICT) | completed | Phase 2 | 125 | GlaxoSmithKlineINDUSTRY | 8 | Dec 8, 2020 | clinicaltrials |
| NCT02219178 | Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 42 | Cancer Trials IrelandNETWORK | 1 | Jul 17, 2020 | clinicaltrials |
| NCT02343406 | Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas(INTELLANCE-2) | completed | Phase 2 | 266 | AbbVieINDUSTRY | 21 | May 22, 2020 | clinicaltrials |
| NCT01787552 | A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | completed | Phase 1 / Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 11 | Apr 15, 2020 | clinicaltrials |
| NCT01466660 | LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung | completed | Phase 2 | 319 | Boehringer IngelheimINDUSTRY | 14 | Apr 7, 2020 | clinicaltrials |
| NCT02690480 | Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer(FLIPPER) | unknown | Phase 2 | 189 | Spanish Breast Cancer Research GroupOTHER | 2 | Feb 5, 2020 | clinicaltrials |
| NCT00721409 | Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer | completed | Phase 2 | 177 | PfizerINDUSTRY | 12 | Nov 4, 2019 | clinicaltrials |
| NCT00974168 | Spinal Cord Compression Re-Treat Study | completed | Phase 2 | 22 | Cancer Trials IrelandNETWORK | 1 | Jul 29, 2019 | clinicaltrials |
| NCT02447666 | Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML) | completed | Phase 2 | 28 | CelgeneINDUSTRY | 13 | Jul 11, 2019 | clinicaltrials |
| NCT01531894 | Continuation Study of the Oral AKT Inhibitor GSK2110183 | completed | Phase 2 | 11 | Novartis PharmaceuticalsINDUSTRY | 5 | Jul 9, 2019 | clinicaltrials |
| NCT01367665 | STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | completed | Phase 2 | 1,232 | Hoffmann-La RocheINDUSTRY | 37 | Jun 6, 2019 | clinicaltrials |
| NCT02306291 | Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML | completed | Phase 1 / Phase 2 | 91 | GlycoMimetics IncorporatedINDUSTRY | 3 | May 17, 2019 | clinicaltrials |
| NCT01381874 | A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy | completed | Phase 2 | 297 | Janssen Research & Development, LLCINDUSTRY | 12 | Apr 11, 2019 | clinicaltrials |
| NCT01485926 | A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.(TCHL Phase II) | completed | Phase 2 | 120 | Cancer Trials IrelandNETWORK | 1 | Aug 6, 2018 | clinicaltrials |
| NCT00809211 | Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 40 | Cancer Trials IrelandNETWORK | 4 | Jul 24, 2018 | clinicaltrials |
| NCT01852292 | Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy | terminated | Phase 2 | 157 | Novartis PharmaceuticalsINDUSTRY | 18 | Jul 24, 2018 | clinicaltrials |
| NCT01440374 | A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia(ASPIRE) | completed | Phase 2 | 162 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 5, 2017 | clinicaltrials |
| NCT00842712 | Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)(CERTO) | completed | Phase 2 | 232 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 8 | Jan 13, 2017 | clinicaltrials |
| NCT01617668 | A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer | completed | Phase 2 | 209 | Novartis PharmaceuticalsINDUSTRY | 12 | Oct 17, 2016 | clinicaltrials |
| NCT01374425 | Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)(MAVERICC) | completed | Phase 2 | 376 | Genentech, Inc.INDUSTRY | 7 | Aug 11, 2016 | clinicaltrials |
| NCT02774278 | A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)(MERIT) | completed | Phase 2 | 264 | Hoffmann-La RocheINDUSTRY | 14 | Aug 8, 2016 | clinicaltrials |
| NCT01147809 | Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag | completed | Phase 2 | 130 | GlaxoSmithKlineINDUSTRY | 13 | Apr 18, 2016 | clinicaltrials |
| NCT01395017 | Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer(LAPC) | completed | Phase 2 | 202 | Otsuka Pharmaceutical Development & Commercialization, Inc.INDUSTRY | 15 | Apr 8, 2016 | clinicaltrials |
| NCT00955175 | Hypofractionated 3-Dimensional Radiation Therapy in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer. ICORG 99-09 | completed | Phase 2 | 60 | Cancer Trials IrelandNETWORK | 1 | Feb 17, 2016 | clinicaltrials |
| NCT00982488 | Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia(START rollover) | completed | Phase 2 | 238 | Bristol-Myers SquibbINDUSTRY | 24 | Jan 22, 2016 | clinicaltrials |
| NCT00718523 | Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer | terminated | Phase 2 | 170 | Translational Research in OncologyOTHER | 8 | Jan 12, 2016 | clinicaltrials |
| NCT00719212 | Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer | completed | Phase 2 | 61 | Translational Research in OncologyOTHER | 7 | Jan 11, 2016 | clinicaltrials |
| NCT01495884 | The Myocet/Lapatinib Study. ICORG 10-03, V5 | terminated | Phase 1 / Phase 2 | 11 | Cancer Trials IrelandNETWORK | 1 | Oct 26, 2015 | clinicaltrials |
| NCT00203372 | Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299) | completed | Phase 2 | 6 | Translational Oncology Research InternationalOTHER | 3 | Oct 12, 2015 | clinicaltrials |
| NCT00430781 | Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer | completed | Phase 2 | 228 | GlaxoSmithKlineINDUSTRY | 13 | May 8, 2015 | clinicaltrials |
| NCT00924443 | A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable | completed | Phase 2 | 69 | Genzyme, a Sanofi CompanyINDUSTRY | 3 | Apr 1, 2015 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials